Program
Cyclosporine
Also written as “cyclosporine”, “Cyclosporine A” and “Ciclosporin”.
Its studies are mostly in Dry Eye Syndromes · Dermatitis, Atopic · Bronchiolitis Obliterans Syndrome · Conjunctivitis, Allergic · Bronchiolitis Obliterans, led by 26 companies.
Drug pageCyclosporine: every studyMany companies study it; this page follows only the 81 they lead. All 388 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 220 open or running | phase 4since Sep 6, 2005 | Sep 6, 2005 | none ahead |
| Pfizerits history only | 80 open or running | phase 4since Sep 13, 2005 | Jun 30, 2004 | none ahead |
| Hoffmann-La Rocheits history only | 70 open or running | phase 4since Jun 30, 2005 | Jun 30, 2005 | none ahead |
| Santen Pharmaceuticalits history only | 50 open or running | phase 3since May 19, 2006 | May 19, 2006 | none ahead |
| AbbVieits history only | 40 open or running | phase 4since Apr 22, 2014 | Apr 17, 2009 | none ahead |
| Zambon SpAits history only | 40 open or running | phase 3since Aug 30, 2018 | Aug 30, 2018 | none ahead |
| Sirion Therapeuticsits history only | 30 open or running | phase 3since Jul 13, 2007 | Jul 13, 2007 | none ahead |
| amsterdam-molecular-therapeuticsits history only | 20 open or running | phase 3since Apr 30, 2009 | Apr 30, 2009 | none ahead |
| apt-pharmaceuticals-incits history only | 20 open or running | phase 3since Sep 17, 2008 | Sep 17, 2008 | none ahead |
| Hanlim Pharm.its history only | 20 open or running | phase 3since Dec 10, 2012 | Dec 10, 2012 | none ahead |
| Innovative Medicalits history only | 20 open or running | phase 4since Jul 5, 2006 | Jul 5, 2006 | none ahead |
| Novaliqits history only | 20 open or running | phase 4since Mar 19, 2024 | Nov 25, 2015 | none ahead |
| perle-bioscience-incits history only | 20 open or running | phase 3since Jan 2, 2013 | Jan 2, 2013 | none ahead |
| Research Insightits history only | 20 open or running | phase 4since Apr 6, 2020 | Apr 6, 2020 | none ahead |
| sigmoid-pharmaits history only | 20 open or running | phase 2since Dec 15, 2009 | Dec 15, 2009 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | phase 4since Apr 8, 2020 | Feb 13, 2016 | none ahead |
| fovea-pharmaceuticals-saits history only | 10 open or running | phase 2since Apr 29, 2010 | Apr 29, 2010 | none ahead |
| isdinits history only | 10 open or running | phase 2since Dec 20, 2007 | Dec 20, 2007 | none ahead |
| LEO Pharmaits history only | 10 open or running | phase 4since Oct 16, 2018 | Oct 16, 2018 | none ahead |
| pari-pharma-gmbhits history only | 10 open or running | phase 3since Apr 11, 2011 | Apr 11, 2011 | none ahead |
| perioc-limitedits history only | 10 open or running | phase 2since Feb 12, 2015 | Feb 12, 2015 | none ahead |
| Pharming Groupits history only | 10 open or running | phase 1since Sep 11, 2012 | Sep 11, 2012 | none ahead |
| spherium-biomedits history only | 10 open or running | phase 2since Aug 4, 2016 | Aug 4, 2016 | none ahead |
| sublimity-therapeutics-holdco-limitedits history only | 10 open or running | phase 2since Jan 31, 2019 | Jan 31, 2019 | none ahead |
| Takedaits history only | 10 open or running | phase 3since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| zhaoke-guangzhou-ophthalmology-pharmaceutical-ltdits history only | 11 open or running | phase 3since Jan 3, 2025 | Jan 3, 2025 | none ahead |
Also a collaborator on its studies: Parexel, Dr. Falk Pharma, Syreon and The Clinical Trial.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Jan 8, 2007.
- Nov 4, 2016Phase 2 study in Anemia, AplasticNovartis · NCT02998645 · 54 enrolled · Brazil, Hong Kong, India and more
- Aug 30, 2018Zambon SpA’s first studies: 2 phase 3 studies in Bronchiolitis ObliteransNew to Zambon SpAZambon SpA · NCT03657342, NCT03656926
- Oct 16, 2018LEO Pharma’s first study: phase 4 study in Dermatitis, AtopicNew to LEO PharmaLEO Pharma · NCT03710044 · Netherlands
- Jan 31, 2019sublimity-therapeutics-holdco-limited’s first study: phase 2 study in Colitis, UlcerativeNew to sublimity-therapeutics-holdco-limitedsublimity-therapeutics-holdco-limited · NCT03844932 · 235 enrolled · United States, Belarus, Bulgaria and more
- Jul 19, 2019Phase 3 study in Bronchiolitis ObliteransZambon SpA · NCT04039347 · 164 enrolled · United States, Austria, Belgium and more
- Sep 25, 2019Phase 2 study in Bronchiolitis Obliterans SyndromeZambon SpA · NCT04107675 · 6 enrolled · France, Germany, Spain
- Oct 25, 2019Phase 3 study in Dry Eye Disease With Severe KeratitisSanten Pharmaceutical · NCT04144413 · 350 enrolled · Czechia, France, Italy and more
- Mar 9, 2020Phase 2 study in Anemia, AplasticNovartis · NCT04328727 · 36 enrolled · China, Japan, South Korea and more
- Apr 6, 2020Research Insight’s first study: phase 4 study in Dry Eye SyndromesNew to Research InsightResearch Insight · NCT04342988 · 74 enrolled · United States
- Apr 8, 2020Phase 4 study in Dry Eye SyndromesSun Pharmaceutical Industries · NCT04357795 · 135 enrolled · United States
- Mar 19, 2024Phase 4 study in Dry Eye SyndromesNovaliq · NCT06329661 · 204 enrolled · United States
- Jun 25, 2024Phase 4 study in Dry Eye SyndromesResearch Insight · NCT06482177 · 52 enrolled · United States
- Jan 3, 2025zhaoke-guangzhou-ophthalmology-pharmaceutical-ltd’s first study: phase 3 study in Moderate to Severe Dry EyeNew to zhaoke-guangzhou-ophthalmology-pharmaceutical-ltdzhaoke-guangzhou-ophthalmology-pharmaceutical-ltd · NCT06766357 · 360 planned · China
- Jun 16, 2025Phase 4 study in Dry Eye SyndromesHoffmann-La Roche · NCT07025811 · 378 enrolled · United States
TargetBeta
“Cyclophilin A modulator”ChEMBL 37, by rule
Studies
The newest 60 of 81 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07025811Dry Eye Syndromes · United States | 4 | Completed | Hoffmann-La Roche | Jul 16, 2026 | 378 |
| NCT06766357Moderate to Severe Dry Eye · China | 3 | Recruiting | zhaoke-guangzhou-ophthalmology-pharmaceutical-ltd | Feb 2026 | 360 |
| NCT06482177Dry Eye Syndromes · United States | 4 | Completed | Research Insight | Jun 5, 2024 | 52 |
| NCT06329661Dry Eye Syndromes · United States | 4 | Completed | Novaliq | Jul 30, 2025 | 204 |
| NCT04357795Dry Eye Syndromes · United States | 4 | Completed | Sun Pharmaceutical Industries | Jun 24, 2022 | 135 |
| NCT04342988Dry Eye Syndromes · United States | 4 | Completed | Research Insight | Dec 31, 2020 | 74 |
| NCT04328727Anemia, Aplastic · China, Japan, South Korea and more | 2 | Completed | Novartis | Jun 10, 2022 | 36 |
| NCT04144413Dry Eye Disease With Severe Keratitis · Czechia, France, Italy and more | 3 | Completed | Santen Pharmaceutical | Jul 14, 2023 | 350 |
| NCT04107675Bronchiolitis Obliterans Syndrome · France, Germany, Spain | 2 | Terminated | Zambon SpA | Jun 16, 2022 | 6 |
| NCT04039347Bronchiolitis Obliterans · United States, Austria, Belgium and more | 3 | Terminated | Zambon SpA | Feb 25, 2026 | 164 |
| NCT03844932Colitis, Ulcerative · United States, Belarus, Bulgaria and more | 2 | Terminated | sublimity-therapeutics-holdco-limited | Apr 14, 2021 | 235 |
| NCT03710044Dermatitis, Atopic · Netherlands | 4 | Withdrawn | LEO Pharma | Aug 2020 | 0 |
| NCT03657342Bronchiolitis Obliterans · United States, Belgium, France and more | 3 | Completed | Zambon SpA | Apr 16, 2024 | 62 |
| NCT03656926Bronchiolitis Obliterans · United States, Austria, Belgium and more | 3 | Completed | Zambon SpA | Mar 12, 2024 | 169 |
| NCT02998645Anemia, Aplastic · Brazil, Hong Kong, India and more | 2 | Completed | Novartis | Nov 3, 2020 | 54 |
| NCT02865356Dermatitis, Atopic · Spain | 2 | Completed | spherium-biomed | Apr 12, 2017 | 36 |
| NCT02688556Keratoconjunctivitis Sicca · United States | 3 | Completed | Sun Pharmaceutical Industries | Nov 2016 | 745 |
| NCT02630563Pediatric Liver Transplantation · United States | 2 | Terminated | Hoffmann-La Roche | Jan 2005 | 9 |
| NCT02617667Dry Eye Syndromes · United States | 2 | Completed | Novaliq | Jul 2016 | 207 |
| NCT02554981Dry Eye Syndromes · United States | 4 | Completed | AbbVie | Mar 24, 2016 | 51 |
| NCT02404025Anemia, Aplastic · Japan | 2 | Completed | Novartis | Jul 5, 2016 | 10 |
| NCT02366585Periodontitis · Sweden | 2 | Completed | perioc-limited | Sep 2016 | 23 |
| NCT02229955Dry Eye Syndromes · Korea, Republic of | 3 | Completed | Hanlim Pharm. | Apr 2014 | 86 |
| NCT02130414Healthy | 1 | Completed | sigmoid-pharma | Jan 2015 | 48 |
| NCT02121847Dry Eye Syndromes · United States | 4 | Completed | AbbVie | Sep 23, 2014 | 40 |
| NCT02091414Heart Transplantation · China | 3 | Completed | Hoffmann-La Roche | Feb 2009 | 36 |
| NCT02005562Kidney Transplantation · France | 3 | Completed | Hoffmann-La Roche | Mar 2009 | 252 |
| NCT01843348Rejection, Psychology · France, Germany | 3 | Completed | Novartis | Mar 23, 2016 | 612 |
| NCT01762657Diabetes Mellitus, Type 1 | 3 | Withdrawn | perle-bioscience-inc | Sep 2015 | 0 |
| NCT01762644Diabetes Mellitus, Type 1 | 3 | Withdrawn | perle-bioscience-inc | May 2016 | 0 |
| NCT01751126Conjunctivitis, Allergic · United States, Croatia, France and more | 3 | Completed | Santen Pharmaceutical | Feb 2016 | 169 |
| NCT01768312Dry Eye Syndromes · Korea, Republic of | 3 | Completed | Hanlim Pharm. | Jul 31, 2013 | 84 |
| NCT01692834Healthy · South Africa | 1 | Completed | Pharming Group | Jan 2010 | 65 |
| NCT01601821Inflammation · Iran, Islamic Republic of | 4 | Completed | Pfizer | Mar 2008 | 245 |
| NCT01552629Dermatitis, Atopic · Austria, France, Germany | 2 | Completed | Novartis | Aug 28, 2013 | 22 |
| NCT01514968Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Feb 2012 | 18 |
| NCT01596062Renal Transplantation · France | 2 | Completed | Novartis | Mar 2013 | 16 |
| NCT01334892Bronchiolitis Obliterans · Germany | 3 | Terminated | pari-pharma-gmbh | Jul 2013 | 130 |
| NCT01276457Transplantation Infection | 3 | Completed | Novartis | Feb 2009 | 223 |
| NCT01120132Conjunctivitis, Allergic · United States | 2 | Completed | fovea-pharmaceuticals-sa | Aug 2010 | 716 |
| NCT01109498Hyperlipoproteinemia Type I · Canada | 3 | UNKNOWN | amsterdam-molecular-therapeutics | Jun 2013 | 14 |
| NCT01033305Mild to Moderate Ulcerative Colitis · Ireland, United Kingdom | 2 | Completed | sigmoid-pharma | Aug 2011 | 118 |
| NCT00991458Laser In Situ Keratomileusis · United States | 2 | Completed | AbbVie | Apr 2011 | 621 |
| NCT00938860Hepatitis C · United States, Belgium, Brazil and more | 4 | Completed | Novartis | May 2013 | 92 |
| NCT00938236Bronchiolitis Obliterans Syndrome · United States, Canada | 3 | Terminated | apt-pharmaceuticals-inc | Sep 2011 | 17 |
| NCT00891306Hyperlipoproteinemia Type I · Canada | 3 | Completed | amsterdam-molecular-therapeutics | Aug 2010 | 5 |
| NCT00884585Conjunctivitis, Allergic · United States, Australia, Canada and more | 3 | Completed | AbbVie | Oct 2010 | 176 |
| NCT00814515Lymphoma, Follicular · France | 3 | Completed | Santen Pharmaceutical | Sep 2009 | 482 |
| NCT00755781Bronchiolitis Obliterans Syndrome · United States, Canada | 3 | Completed | apt-pharmaceuticals-inc | Sep 2011 | 284 |
| NCT00739349Dry Eye Syndromes · United States | 2 | Completed | Santen Pharmaceutical | Jan 2009 | 132 |
| NCT00578370Psoriasis · Germany | 2 | Completed | isdin | Apr 2008 | 25 |
| NCT00549289Dry Eye Syndromes · United States | 3 | Completed | Sirion Therapeutics | ||
| NCT00548301Dry Eye Syndromes · United States | 3 | Completed | Sirion Therapeutics | ||
| NCT00518375Kidney Transplantation | 4 | Completed | Pfizer | 250 | |
| NCT00507793Kidney Transplantation | 4 | Completed | Pfizer | 385 | |
| NCT00504543Kidney Transplantation · Argentina, Australia, Austria and more | 2 | Completed | Novartis | Apr 2011 | 311 |
| NCT00502073Dry Eye Syndromes · United States | 3 | Completed | Sirion Therapeutics | ||
| NCT00438360Chronic Plaque Psoriasis · Italy | 3 | Completed | Novartis | Nov 2007 | 243 |
| NCT00428064Renal Transplantation | 3 | Completed | Pfizer | 408 | |
| NCT00419926Kidney Transplantation · Switzerland | 4 | Completed | Novartis | Jun 2009 | 313 |
How it is read
Names in the registry
- “cyclosporine”, 12 entries
- “Cyclosporine”, 10 entries
- “Cyclosporine A”, 6 entries
- “Ciclosporin”, 4 entries
- “Liposomal Cyclosporine A”, 3 entries
Codes read as this program: NOVA22007.
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 15 studies
- Dermatitis, Atopic, 5 studies
- Bronchiolitis Obliterans Syndrome, 4 studies
- Conjunctivitis, Allergic, 4 studies
- Bronchiolitis Obliterans, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.